These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21884955)

  • 1. Chronic kidney disease and cardiovascular therapeutics: time to close the evidence gaps.
    Chang TI; Chertow GM
    J Am Coll Cardiol; 2011 Sep; 58(11):1162-4. PubMed ID: 21884955
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis.
    Badve SV; Roberts MA; Hawley CM; Cass A; Garg AX; Krum H; Tonkin A; Perkovic V
    J Am Coll Cardiol; 2011 Sep; 58(11):1152-61. PubMed ID: 21884954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systolic heart failure.
    Vitale J; Carbone F
    N Engl J Med; 2010 Apr; 362(16):1545; author reply 1545-6. PubMed ID: 20410523
    [No Abstract]   [Full Text] [Related]  

  • 4. Beta blockers in systolic heart failure.
    Lindsay DA
    Aust Fam Physician; 2008 Jun; 37(6):391; author reply 391. PubMed ID: 18597983
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical inquiry: what is the best beta-blocker for systolic heart failure?
    Hulkower S; Aiken BA; Stigleman S
    J Fam Pract; 2015 Feb; 64(2):122-3. PubMed ID: 25671531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. We should not hesitate to use beta-blockers for systolic heart failure with concomitant renal dysfunction.
    Matsuda N
    Circ J; 2010 Aug; 74(8):1526-7. PubMed ID: 20647630
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of Early Treatment With Ivabradine Plus Beta-blockers on Long-term Outcomes in Patients Hospitalized With Systolic Heart Failure.
    Hidalgo F; Carrasco F; Castillo JC; Anguita M
    Rev Esp Cardiol (Engl Ed); 2018 Dec; 71(12):1086-1088. PubMed ID: 29373253
    [No Abstract]   [Full Text] [Related]  

  • 8. Prescription Bias in the Treatment of Chronic Systolic Heart Failure.
    Arfsten H; Goliasch G; Pavo N; Ulmer H; Hülsmann M; Stefenelli T;
    Ann Intern Med; 2020 Jan; 172(1):70-72. PubMed ID: 31569211
    [No Abstract]   [Full Text] [Related]  

  • 9. Heart rate reduction is probably not the main beneficial mechanism by which beta blockade improves outcome in patients with systolic chronic heart failure.
    Fragasso G; Salerno A; Margonato A
    Am J Cardiol; 2008 Aug; 102(4):506-7. PubMed ID: 18678315
    [No Abstract]   [Full Text] [Related]  

  • 10. Beta-blockers for heart failure: why you should use them more.
    Ong HT; Kow FP
    J Fam Pract; 2011 Aug; 60(8):472-7. PubMed ID: 21814642
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of systolic heart failure in the elderly: an evidence-based review.
    Arif SA; Mergenhagen KA; Del Carpio RO; Ho C
    Ann Pharmacother; 2010 Oct; 44(10):1604-14. PubMed ID: 20841514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug treatment for chronic systolic heart failure.
    Mörike K; Sindermann JR
    Thorac Cardiovasc Surg; 2010 Feb; 58 Suppl 2():S170-2. PubMed ID: 20101534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in the Use of Guideline-Directed Therapies Among Dialysis Patients Hospitalized With Systolic Heart Failure: Findings From the American Heart Association Get With The Guidelines-Heart Failure Program.
    Pandey A; Golwala H; DeVore AD; Lu D; Madden G; Bhatt DL; Schulte PJ; Heidenreich PA; Yancy CW; Hernandez AF; Fonarow GC
    JACC Heart Fail; 2016 Aug; 4(8):649-61. PubMed ID: 27179827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contemporary medical management of systolic heart failure.
    Nair AP; Timoh T; Fuster V
    Circ J; 2012; 76(2):268-77. PubMed ID: 22240600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ACE-inhibitors, beta-blockers or the combination in heart failure: is it just an A-B-C ? : editorial to: effects of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure by Rosenberg et al.
    de Boer RA; van Veldhuisen DJ
    Cardiovasc Drugs Ther; 2008 Aug; 22(4):261-3. PubMed ID: 18418705
    [No Abstract]   [Full Text] [Related]  

  • 16. [Medical management of chronic systolic heart failure].
    Galinier M
    Rev Prat; 2010 Sep; 60(7):941-6. PubMed ID: 21033491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-adrenergic blockers in chronic systolic heart failure secondary to Chagas' disease.
    Dávila DF; Donis JH; Torres A; Gottberg CF; Ramoni-Perazzi P; Arata de Bellabarba G
    Int J Cardiol; 2008 Aug; 128(1):1-4. PubMed ID: 18378338
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacological management of chronic heart failure: old drugs, new drugs and new indications.
    Lim WY; Woldman S
    Br J Hosp Med (Lond); 2013 Feb; 74(2):C18-22. PubMed ID: 23411909
    [No Abstract]   [Full Text] [Related]  

  • 19. Switching to once-daily evidence-based [beta]-blockers in patients with systolic heart failure or left ventricular dysfunction after myocardial infarction.
    Albert NM
    Crit Care Nurse; 2007 Dec; 27(6):62-72. PubMed ID: 18032686
    [No Abstract]   [Full Text] [Related]  

  • 20. [Pharmacokinetics of a new beta-receptor blockader (terbuclomin) in kidney failure].
    Schweiger J; Renner D
    Verh Dtsch Ges Inn Med; 1974; 80():667-9. PubMed ID: 4156116
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.